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Pharmaceutical products are intended to cure disease, reduce pain and suffering, prolong life, and correct
metabolic deficits in patients. However, the potential patient population is intrinsically genetically hetero-
genous, and this factor complicates the evaluation of data on all aspects of safety evaluation of new drugs.
Often the genetic heterogeneity is related to drug metabolizing capacity, but recent evidence suggests that
heterogeniety in repair capacity as well as structural integrity ofthe chromatin (fragile X) have been shown
tobe relevant. Because drugs arebiologically active and may have more than one type ofeffect, the evaluation
ofalarge numberofparameters is necessary in arriving at arational estimate ofpotential risk. Inthis paper,
several specific examples of risk assessments and some generic genotoxicity questions that are recurrent,
including the question ofthe relevance ofin vitro chromosomal aberration induction at high dose/sampling
time, are raised. Otherexamplesofthe kinds ofconcerns fromthe safetyevaluation ofU-48753E, U-54461, and
U-68,553B are discussed. The drug U-48753E was discovered to be slightly mutagenic in the AS52 assay, and
significant effortswereexpended inevaluation ofthe metabolism-based generationofareactive intermediate.
ThedrugU-54,461was showntobecapable ofbreakingchromosomes in vitro butextensive in vivodataaswell
as a variety of other studies served to reduce the level of concern substantially. The induction of apparent
chromosome breaks and gapsby U-68553B was shown to be an artifact that was restricted to a single cell line
ofrodentcells.These diverseexamples ofriskassessments illustrate the complexityofrisk/benefitanalysis in
drug development.
Introduction
The focus of this conference, as suggested by its title
"Environmental Mutagenesis in Human Populations at
Risk," is a very important aspect ofenvironmental muta-
genesis. This paper deals with some ofthe considerations
relating to this topic from the perspective of the develop-
ment of human pharmaceutical products. Mutagens are
present in the natural environment (1) and in the "syn-
thetic" environment with which we have surrounded our-
selves. For example, the simple act of cooking food
produces potent mutagens. Evenuncooked food and other
environmental constituents can contain mutagens. Many
pesticides are known to be mutagenic in short-term tests,
and the care taken in handling these compounds should
reflect the degree of hazard. Thus, the task of fully
comprehending the problem of environmental muta-
genesis in human populations at risk is not trivial. Part of
the effortwe devote tothisworkisinidentifyingmutagens
and potential mutagens. Another part must be devoted to
study of the populations exposed to the potential muta-
gens, and still a large part of the job is estimating, no
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matter how primitively, the degree ofimpact ofmutagen
exposure. The dauntingdifficulty oftheproblem is clearly
delineated (2) by the case of ionizing radiation, where
despite the devotion of significant resources over many
years, only limited estimates are possible. Carrying out
such extensive scientific investigationfor anyotherpoten-
tialmutagenic agentishighlyunlikely. The caseforchemi-
cals and drugs is even more difficult because of the
complications of absorption and metabolism.
In the pharmaceutical industry, "lead" (or prototype)
compounds areoftentestedformutagenicproperties atan
early stage, usually before a material is introduced to
humans for the first time. Here we focus on efforts to
identifyandevaluatemutagensusingshort-termtestsand
todeterminewhetherthesefindings arerelevantinvivoin
humans. This area presents the most direct application of
environmental mutagenesis because these materials are
known to be biologically active and are intended to be
administered to humans, sometimes in relatively large
quantities. Inmanycountries (3-6), therelevance ofmuta-
genicity to the overall hazard evaluation of drugs is well
established, although the details of the process vary
greatly from one country to the other. Of course, for
companies and other institutions (like the World Health
Organization) intending to produce and distribute drugs
worldwide, safety to the consuming public is paramount.
We begin by considering some of the regulatory require-AARON ET AL.
ments and the need for further harmonization of guide-
lines. We then give several examples ofmaterials thathave
shown positive responses in short-term tests and discuss
some of the factors that were considered in developing a
risk assessment for these materials. Finally, we briefly
discuss several techniques we are using to decrease the
costofevaluation and toimprove ourabilitytounderstand
the significance ofpositive findings.
General Considerations
Regulatory authorities in Europe, Japan, and the
United States have developed extensive guidelines for the
mutagenicity data needed to support registration of new
drugs and chemicals (3-7). Virtually all these countries
haveacknowledged thattheneedforsuchdataisdrivenby
both the potential risk from somatic mutation as well as
fromgermcellmutation. However,thedifficultyofobserv-
ing germinal mutagenesis in the offspring of exposed
population (2) due to the small populations that can be
observed as well as the ethical restraint imposed on
continued, voluntary exposure of humans to such mate-
rials has generally led to a lack of efforts to regulate on
thatbasis (8). Thus, the mutagenicitydatacurrentlybeing
produced in the countriespreviouslymentioned are gener-
ally used to evaluate the carcinogenic potential of a com-
pound.
Human drugs are used for a variety ofpurposes, from
the straightforward relief of pain to the elimination of
parasites and cure ofmicrobial disease. These conditions
varyenormouslyin severityandinthe consequences ofnot
using the drugs, and therefore the mutagenicity of the
drugs (particularly in vitro mutagenicity) must be care-
fullyweighed in light ofthe benefits. For example, cancer
is a dread disease that takes many lives in all countries,
and in the United States it is the contributing cause of
death in about one-fourth ofall deaths. AIDS is a particu-
larly significant disease with no chance of survival. Dis-
eases such as cancer and AIDS are often treated with
particularly aggressive therapy. In the case of cancer,
almostalloftheroutinelyused,effective chemotherapeutic
agents are mutagens and may be carcinogenic. AZT used
in the treatment ofAIDS as well as the newer compounds
used are generally mutagenic in one or more routine
assays that evaluate potential carcinogenicity. Other dis-
eases from the common cold to insomnia are less serious,
and thercfore the kinds ofsideeffects that aretolerable do
notinclude mutagenicity. The problem ofrisk assessment
for drugs must be solved using a holistic approach that
may well provide a model for the assessment of human
populations at risk from other potential environmental
mutagens. This means that all aspects ofthe risk assess-
mentmustbeevaluated, e.g., exposure,whethertheriskis
voluntary, whether the population at risk is the population
exposed, and whether the risk is real or only perceived.
The Upjohn Test Battery
The evaluation of the safety of a proposed new drug
begins with subjecting it to several short-term tests. The
timing of the assays is dictated in some measure by the
availability of the drug because at very early stages of a
drug's development, verylittle ofthe drugis available and
therefore few safety tests can be performed. Usually the
firstassayisamicrobial assayformutagenesis such asthe
Ames test with Salrmonella typhimurium. This assay is
simple, cheap, andreasonablygood atidentifyingbacterial
mutagens (9). Our experience with drug candidates has
beenthatabout5-10% ofcompounds chosenrandomly are
positive inthistest(ifhomologous series ofcompounds are
treated as single entities), and this levelis also reflected in
the Japanese experience (3) with a variety of materials;
clearly the high prevalence ofmutagens in the data set of
the National Toxicology Program (10) is not reflective of
the universe of chemicals.
TheAmestestisfollowed oraccompaniedbytests ofthe
ability ofthe compound to reach and damage mammalian
DNA. This may take the form ofthe in vitro unscheduled
DNA synthesis (UDS) assay or other assays of DNA-
damaging ability. Such an assay is needed because the
bacterial chromosome is significantly different from that
of the eukaryote. In the UDS assay, rat hepatocytes are
exposed to drug, and theincorporation ofDNAprecursors
during repair is followed with autoradiographic tech-
niques.
The Ames assay and UDS are carried out at relatively
early stages ofthe development process and are followed
by more elaborate tests such as in vitro cytogenetic
assays, mammalian cell mutation assays and in vivo
cytogenetic assays when sufficient drug becomes avail-
able. Ourexperience hasbeenthatapproximately5-10%of
these potential drug candidates produce positive
responses. This of course excludes anticancer agents
which are routinely positive. This figure (5-10%) bears
emphasizing because it is significantly lower than the
frequency of positives among the National Toxicology
Program (NTP) database of compounds and reflects the
selected nature of those compounds. The importance of
this discrepancy between the NTP data and that ofscien-
tists in the pharmaceutical industry (many colleagues in
thepharamceuticalindustryandthe contracttestinglabo-
ratory industrywould probably confirm the frequency) is
that the prevalence ofpositives in the data set determines
to some extentthereliabilityofthe estimates ofsensitivity
and selectivity at lower and therefore more realisitic prev-
alence rates.
Positive responses in these early tests, i.e., compounds
which raise a "red flag," are given significantly greater
scrutiny. Unlikethe process used inthe NTP evaluation of
mutagenic potential of a nonrandom set of carcinogens
(10), further study of the potential for metabolism, com-
plications caused by high-dose toxicity, and species specif-
icity are often aggressively evaluated. Our experience has
been that mechanistic follow-up ofthese screening results
often reveals them to be due to species or system-specific
effects. Even when the follow-up reveals confirmatory
information, such follow-up is warranted because better
decisions are possible concerning alternatives of struc-
ture, for example.
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Other Information Used in Risk
Assessments
Agents that are capable ofreaching and damaging the
DNA of human chromosomes represent a real risk and
must therefore be taken seriously. However, a positive
response in a particular short-term test is not definitive
proofthat the compound is capable ofreaching or damag-
ing human DNA. One of the key factors leading to a
discrepancy between the result in a bacterial or cell cul-
ture assay and the expected outcome in humans is a
difference in the metabolism of the compound in vivo.
Also, theseinvitro assays do notreflectthehumanbody's
absorption, distribution, and elimination ofthe compound.
Thus, theprobabilitythattheactiveingredientinthedrug
is the active principle in the mutational end point must be
high before significance can be attached to the outcome of
an in vitro short-term test. Furthermore, the amount of
relevantchemicalspeciesmustbeproducedinvivo. Thein
vivo (whole animal) system is much more complicated in
terms of distribution and excretion than an in vitro bac-
terial or cell culture assay because many time-dependent
factors come into play. Even a factor like mutagenicity,
whichwould notbeexpected to have athreshhold invitro,
may have a physiologically mediated practical threshhold
in vivo. Unfortunately, the kind of data necessary to
understand these factors often depends on availability of
radiolabeled drugs and sophisticated analytical tech-
niques that are available only in later stages of drug
development.
Another critical factor that is often difficult to gauge is
the likely exposure ofhumans to the drug. Clearly, human
consumption of a drugwillbeless than kilograms per day,
butthe disease entityand factorsrelated tobioavailability
(the fraction that will reach the circulation following oral
exposure), potency (plasma concentration required to pro-
duce the desired therapeutic effect), and biological per-
sistence (half-life in the body) often determine the
exposure. All these factors will similarly impact the risk
assessments for nondrug entities but may be even harder
to evaluate because ofthe lack ofradiolabeled compound,
complex nature ofthe material, or other reasons.
One factorthatis considered in the case ofdrugs, which
may not have an analogy in assessment ofother environ-
mental mutagens, is the side effect profile ofthe competi-
tor drugs. For example, AZT causes severe bone marrow
suppression and a constellation of other effects including
mutagenesis in someshort-termtests,whichlimitthetime
a patient can take the drug even ifhe or she can afford it.
The combination oftheimmunosuppression (which maybe
the reason for the appearance ofthe enhanced frequency
ofKaposi's sarcoma in AIDS) with the mutagenic proper-
ties of AZT would tend to support caution even in the
earlier stages of AIDS therapy if truly life-saving AIDS
therapybecomes a reality. An alternative drugwith equal
orgreaterpotency(efficacy) would in all likelihood replace
AZT ifit had significantly reduced side effects. In fact, a
potent anti-AIDS drug with reduced genotoxic potential
compared to nucleotide analogs would be preferable
because the characteristic of this disease is immunosup-
pression. Another trade-off totally unrelated to AIDS is
the case ofU-68553B, a potential antischizophrenic drug.
In this case the value judgment relates the potential
mutagenic risks suggested by in vitro results to the
existing therapies, which are so onerous that one of the
biggest problems is patient compliance (assuring that the
patients take the drug). Several specific examples will
illustrate some ofthe kinds ofconsiderations in the phar-
maceutical risk assessment setting.
U-48753E. U-48753E was a promising antidepressant
drug ofa novel class. Depression afflicts manymillions of
people throughout the world. In the early development of
this drug (11), a range of short-term genetox assays was
carried out including theAmes test and the in vitro UDS
assay, which were both negative. After the compound was
in clinical trials, it was found to produce mutations in the
Chinesehamsterovary/HPRTassay, oneassayforassess-
ingtheabilitytoinduce genemutationsineukaryoticcells.
Mutagenesis was only observed in the presence of S9
metabolic activation, and the increases were sporadic.
More consistent mutagenicity was observed when the
genetically engineered cell line AS52 was used as the
tester strain, again, only with an added metabolic activa-
tion system. This findingled Upjohn to stop clinical trials
and initiate an investigation ofthe mutagenic risk associ-
ated with the drug (11).
The drug U-48753E is like many drugs that contain
methylamine substituents. These kinds ofcompounds are
commonly demethylated by mammalian enzymes to yield
formaldehyde equivalents. In fact, this compound was
found toproduce formaldehyde inthe presence ofratliver
enzymes. Furthermore, the addition of formaldehyde
dehydrogenase to the incubation mixture ameliorated the
mutagenicity, reinforcingthehypothesisthattheobserved
mutations were probably induced by liberated formalde-
hyde in vitro. Formaldehyde dehydrogenase is a potent
and ubiquitous mammalian enzyme and is capable ofren-
dering low concentrations of formaldehyde harmless in
vivo. Although there is some evidence of induction of
cancer by formaldehyde at the site of inhalation, these
studiesallinvolvehighexposureandmaybeexplained as a
consequence ofirritation rather than direct genotoxicity.
Clearly, formaldehyde is mutagenic, but it is also rapidly
metabolized and reactswith avarietyofelectrophilic sites
tosignificantlydecreasethepotentialfordirectreactionin
the nucleus with DNA. Nevertheless, the formaldehyde
which could theoretically be produced by U-48753E
reveals that liberated formaldehyde from this source
would yield less than 0.01% of the normally circulating
levels of formaldehyde equivalents. Because this was not
viewed as a significant perturbation ofthe formaldehyde
pools, clinical trials were resumed.
U-68553B. U-68553B was an antischizophrenic drug
candidate. Early in the development process, the com-
poundsintheanalogseriesrevealed atendencytoproduce
mutations in the Ames test. Interestingly, the effect was
only observed in the presence of S9 metabolic activation.
Several experiments were carried out that supported the
proposition that the mutagenicity was mediated by reac-
tive oxygen or otherradicals. However, the compound was
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unable to induce mutations in mammalian cells in vitro,
norwas any evidence ofmutagenicity seen in vivo.
U-54461. Bropirimine (U-54461) is abiological response
modifier that is thought to act through the induction of
lymphokines. It was originally developed as a potential
anticancer agent to be used after tumor debulking
through surgery. A decided advantage of this kind of
therapy (immune stimulation) is the lack of side effects
generally associated with more traditional chemotherapy.
Several mutagenicity studies with bropirimine failed to
produce enhanced mutagenesis. However, the compound
was shown to induce chromosome aberrations in vitro in
the absence of activation at very high doses (12). Testing
failed to offer a consistent explanation for the positive in
vitro results (13), and no evidence ofin vivo mutagenicity
was found (14). Although a detailed mechanistic explana-
tion ofsuch observations has seldom been possible, many
workers are coming to the conclusion that isolated high-
dose positives, particularlywhen accompanied by toxicity,
are irrelevant to the assessment ofrisk for mutation.
U-73975. The final example is that of the anticancer
agent U-73975, andwe combine this discussion with men-
tionofsomerecentresults onthedetection ofmutagenesis
in the primate. This drug is, like many cytostatic anti-
cancer agents, averypotent mutagen. Byverypotent, we
mean that it produces mutations at vanishingly small
doses(15,16). U-73975isveryspecificinitsbindingproper-
ties, preferring adenines in the DNA to the exclusion of
guanines. The binding data were obtained using naked
DNA in vitro, and for a long time little information was
available in vivo. However, the result oftesting this mate-
rial in the Ames test with Salmonella typhimurium
strain TA102 revealed that it was a particularly potent
mutagen in this strain at doses that were negative in the
other common strains; strain TA102 was genetically
engineered to detect A-T base pair mutagenesis, the only
Ames test strain with this property. The extreme specif-
icity ofthe binding combined with the high potency sug-
gest that the compound might be highly selective, and
clinical trials are now in progress.
This is a class of compounds which has a very high
specificity for adenine sites in DNA, and we are in the
process of evaluating the mutational spectra in systems
that have eukaryotic chromosomes. Specifically, we are
collaborating (15) with Ken Tindall of the National
Institute of Enviromental Health Sciences in evaluating
the spectrum ofU-73975 induced mutants in theAS52 cell
line. Preliminary results suggest that about half of the
mutants are functional deletions, but a sizeable number of
intragenic changes appear to have been induced. We are
currently sequencing these mutants to determine where
the mutations have occurred, but there are several copies
of the consensus sequence for binding within the struc-
tural gene.
Foravarietyofreasons,wealso studiedtheinduction of
mutations in the cynomolgus monkeyby U-73975, and the
results may indicate a potential problem with the use of
HPRT assays for monitoring. We treated three monkeys
with U-73975 and monitored the appearance of HPRT
mutations in theperipheral blood using an adaption ofthe
technique of Albertini (16). In this experiment (unpub-
lished data),we alsomonitoredthe appearance ofchromo-
some aberrations in the peripheral blood using standard
cytogenetic techniques. Our previous experience (16,17)
had shown that mutants appeared in the periphery only
after a period ofseveral weeks. In these experiments the
frequency of cells with gross rearrangements clearly
showed induction of complex rearrangements, but we
failed to find mutant T-cells even though we followed the
animals for a significant period beyond that found to be
necessary in earlier experiments. We do not yet under-
stand this result because in mammalian cells in culture,
induction ofmutationswas observable atverylowlevels of
U-73975. Thus it seemsprudentto addthe note ofcaution
that a negative result in an in vivo HPRT assay with
T-cells may significantly underestimate the potential for
mutation induction.
Alternative Methods of Evaluation
Returning for just a moment to the technologies for
evaluatingdrugs, wewant to mention two techniques that
are particularly exciting in the context of genetic toxicol-
ogyforpotentialdrugs.Weshouldpointoutthefactthatin
theearlystages ofdrugdevelopment,verylittlecompound
is typically available, and this factor severely limits the
amount of testing that is possible. Particularly in those
cases inwhich a series ofanalogs are available, structural
analysis often provides insight into the mechanism
through which the mutagenicity is manifest. We have
foundtheSpiralSalmonellaassay,originallyintroducedby
Claxton and co-workers (18,19) to beparticularly useful in
identifying potent mutagens and potentially useful for
structure-toxicity evaluation of a series of analogs. The
chief benefit of the system is that relatively small quan-
tities ofdrug [or complex environmental mixture (19)] are
required for a test. However, this system suffers from the
factthatcompounds that arewater soluble diffuse into the
agar and hence appear less mutagenic than might be the
case in the standard plate incorporation or preincubation
assay. Nevertheless, we have found this method useful in
structure-activity evaluation (20) and recommend its con-
sideration in situations in which limited quantity of test
substance precludes more extensive testing.
Another technique that has proven interesting in the
recentpastiscomputerized structureactivityprogramsin
toxicology. The program that we use is called TOPKAT
and was written by HeathDesigns Incorporated. Using
this system, it is possible to estimate the toxicity for
several end points including the oral LD50 in rats, eye
irritation, dermal irritation, and mutagenicity and car-
cinogenicity. This systemsuffersfromthe same shortcom-
ings as all computerized systems ofthis kind, namely, itis
limited by the database used in "teaching" the program
what aspects ofmolecules are toxic. The difficulty is that
most new drugs are novel chemical entities and therefore
have moieties that may be unusual for the database and
thus hard to estimate. However, by careful dissection of
the molecules into component parts, it is often possible to
arrive atlikelyestimates ofthetoxicity.Thisisnottheonly
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system available for the prediction of carcinogenesis of
compounds based principally on structural features (9,21-
24), however, TOPKAT has the advantage of being com-
pact enough to fit on a personal computer, and it is
commercially available.
Summary
In summary, anticipating the effect of environmental
mutagenesis in human populations at risk is difficult.
Identifying the potential mutagenic materials is only the
first step in the process, which must include significant
exposure estimates and study of metabolism. Competing
risks must be weighed. Dose response must be ascer-
tained, and aholisticapproachtotheriskassessmentmust
be adopted. Particularly, in those cases of low-level
environmental exposure, creative methods must be devel-
oped to evaluate the potential hazard using computerized
techniques and miniaturized and automated procedures.
Perhaps the approaches used in pharmaceutical research
can be adapted to the problem and thereby improve the
throughputandreliabilityoftheprocess. Structures ofthe
molecules mentioned in this manuscript are given else-
where (15,25).
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